利伐沙班与华法林治疗非瓣膜性心房颤动对比研究

Comparative study of rivaroxaban and warfarin in treatment of nonvalvular atrial fibrillation

目的探讨利伐沙班与华法林抗凝治疗非瓣膜性心房颤动的临床疗效及安全性。方法抽取2014年5月—2016年2月98例非瓣膜性心房颤动患者,随机分为研究组(49例)与对照组(49例)。对照组采用华法林治疗,研究组采用利伐沙班治疗。统计两组栓塞事件、出血事件及不良反应发生率。结果研究组栓塞事件发生率为8.16%,对照组为10.20%,两组对比差异无统计学意义(P>0.05);研究组出血发生率为4.08%,不良反应发生率为16.32%,分别低于对照组的20.40%和38.76%,两组对比差异有统计学意义(P<0.05)。结论采用华法林与利伐沙班对非瓣膜性心房颤动患者实施抗凝治疗均可取得显著疗效,可明显降低栓塞事件发生率,但利伐沙班出血事件及不良反应发生率低于华法林,具有一定安全性。

Objective To evaluate the clinical efficacy and safety of rivaroxaban and warfarin in the treatment of nonval- vular atrial fibrillation. Methods From May 2014 to February 2016, 98 patients with nonvalvular atrial fibrillation were randomly divided into study group （49 cases） and control group （49 cases）. The control group was treated with warfarin and the study group treated with rivaroxaban. The incidence of embolization, bleeding and adverse reactions were recor- ded. Results The incidence of embolism was 8.16% in the study group and 10.20% in the control group. There was no significant difference between the two groups （ P 〉 0. 05 ）. The incidence of bleeding was 4.08% in the study group and the incidence of adverse reactions was 16.32% , which was lower than 20.40% and 38.76% in the control group respectively. There was significant difference between the two groups （P 〈 0. 05）. Conclusion Warfarin and rivaroxa- ban can significantly reduce the incidence of thromboembolic events in patients with nonvalvular atrial fibrillation. How- ever, the incidence of adverse events and rates of adverse events in the rivaroxaban group were significantly lower than those in the control group Farin, with a certain degree of security.